A recent study found that women with overactive bladder who received antimuscarinics were 38% more likely to be diagnosed with depressive disorder within the next 3 years than those who did not receive antimuscarinics.
A recent study found that women with overactive bladder who received antimuscarinics were 38% more likely to be diagnosed with depressive disorder within the next 3 years than those who did not receive antimuscarinics.
Although antimuscarinics can significantly depress bladder contractions and improve symptoms by blocking muscarinic receptors, studies have found that several unwanted side effects frequently occur when patients with overactive bladder receive the drugs.
“This population-based retrospective cohort study found that use of antimuscarinics was associated with subsequent depressive disorder in women with overactive bladder,” said Li-Ting Kao, senior author of The Journal of Clinical Pharmacology study.
Additional Information
Link to Study: http://onlinelibrary.wiley.com/doi/10.1002/jcph.890/full
About Journal
The Journal of Clinical Pharmacology (JCP) is the flagship publication of the American College of Clinical Pharmacology. Published since 1961, the journal has been providing readers with access to original research, special reviews, commentaries, and case reports on all phases of drug development. A monthly, international peer-reviewed journal, The Journal of Clinical Pharmacology (JCP) transitioned to an online-only format beginning in 2013.
Penny Smith
+44 (0)1243 770448
sciencenewsroom@wiley.com